Washington Research Foundation (WRF) has awarded a $250,000 phase 2 technology commercialization grant to support the development of a novel gene therapy for the treatment of severe asthma and eosinophilic esophagitis by investigators Sinduja Marx, Ph.D., and Jason Price, Ph.D., postdoctoral scholars at the Olson Lab in Seattle Children’s Research Institute. This project is in collaboration with Benaroya Research Institute’s Karen Cerosaletti, Ph.D., and Steven Ziegler, Ph.D. WRF previously provided Dr. Price with a phase 1 grant of $58,000 that supported the generation of antibody targets that will be used during the phase 2 antibody discovery campaign and the development of a new gene therapy platform.
